

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6896765

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SYMBIOMIX THERAPEUTICS, LLC	12/29/2019
RECEIVING PARTY DATA	
Name:	LUPIN INC.
Street Address:	HARBORPLACE TOWER
Internal Address:	111 S. CALVERT STREET, 21ST FLOOR
City:	BALTIMORE
State/Country:	MARYLAND
Postal Code:	21202
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17335016
CORRESPONDENCE DATA	
Fax Number:	(212)692-1020
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	212-692-1000
Email:	scunningham@duanemorris.com
Correspondent Name:	DUANE MORRIS LLP; ATTN: CINDY YANG
Address Line 1:	1540 BROADWAY
Address Line 4:	NEW YORK, NEW YORK 10036-4086
ATTORNEY DOCKET NUMBER:	Y7781-00082-CON
NAME OF SUBMITTER:	CINDY YANG
SIGNATURE:	/Cindy Yang/
DATE SIGNED:	09/01/2021
Total Attachments: 7	
source=FILED-Confirmatory Assignment-Symbiomix to Lupin#page1.tif	
source=FILED-Confirmatory Assignment-Symbiomix to Lupin#page2.tif	
source=FILED-Confirmatory Assignment-Symbiomix to Lupin#page3.tif	
source=FILED-Confirmatory Assignment-Symbiomix to Lupin#page4.tif	
source=FILED-Confirmatory Assignment-Symbiomix to Lupin#page5.tif	

source=FILED-Confirmatory Assignment-Symbiomix to Lupin#page6.tif
source=FILED-Confirmatory Assignment-Symbiomix to Lupin#page7.tif

CONFIRMATORY PATENT ASSIGNMENT

This Confirmatory Patent Assignment ("Assignment") is made by and between Symbiomix Therapeutics, LLC, a Delaware limited liability company ("Assignor"), and Lupin Inc., a Delaware corporation with its principal place of business at Harborplace Tower, 21st Floor, 111 S. Calvert Street, Baltimore, Maryland 21202 ("Assignee").

WHEREAS, Assignor is the owner of all right, title and interest in and to the inventions and related U.S. and foreign Patents and applications for Patent listed in Schedule A, and the goodwill of the business in connection therewith (collectively, the "Inventions");

WHEREAS, Assignor desires to assign and transfer all right, title and interest in and to said Inventions and any Patents that may be granted therefor to Assignee, to ensure that all such right, title and interest are assigned and transferred to Assignee, and to execute and deliver this Assignment to Assignee;

WHEREAS, Assignee desires to acquire all right, title and interest in and to said Inventions and any Patents that may be granted therefor, to ensure that all right, title and interest thereto are transferred to Assignee, and to receive this Assignment from Assignor; and

WHEREAS, Assignor and Assignee agree that this Assignment is made as a distribution of assets from a disregarded subsidiary (Assignor) to its parent (Assignee) in connection with the dissolution of Assignor.

NOW, THEREFORE, in consideration of Ten U.S. Dollars (US\$10.00) and other good and valuable consideration, the receipt and sufficiency of which are hereby expressly acknowledged, Assignor hereby sells, assigns and transfers unto Assignee the entire right, title and interest for the United States and all other countries in and to said Inventions, including the aforesaid Patents and applications for Patent, all original, divisional, continuation, national/regional stage, substitute or reissue applications and patents applied for or granted therefor in the United States and all other countries, all rights under any applicable international conventions and treaties (e.g., the International Convention for the Protection of Industrial Property), including all rights of priority from the filing of said applications and all goodwill associated therewith, and all rights to sue for past, present and future infringement and to collect of damages thereof, and the U.S. Commissioner of Patents and Trademarks and relevant foreign patent offices are hereby authorized and requested to issue all patents on said Inventions or resulting therefrom to said Assignee herein, as Assignee of the entire right, title and interest therein; and the Assignor, for itself and its respective legal representatives do hereby agree and covenant, without further remuneration, to execute and deliver all Patents and all original, divisional, continuation, regional/national stage, substitute, reissue and other applications for Patent on said Inventions and all assignments thereof to said Assignee, its successors, or its assigns, to communicate to said Assignee, its successors, its assigns, or its representatives all facts known to the Assignor respecting said Inventions, whenever requested, to testify in any interferences, post-grant reviews, *inter partes* reviews, oppositions, litigations, or other legal or regulatory proceedings in which any of said Patents or applications for Patent may become involved, to

DM2\10804161.1

QB\60946862.2

PATENT
REEL: 057361 FRAME: 0330

sign all lawful papers, make all rightful oaths, and to do generally everything necessary to assist Assignee and its respective successors, assigns and nominees to obtain patent protection for said Inventions in the United States and all other countries, the expenses incident to said applications to be borne and paid by said Assignee.


The Effective Date of this Assignment is December 29, 2019.

This Assignment is governed and interpreted by the laws of the State of Delaware without regard to conflict of law principals. Any legal action or dispute involving this Assignment shall be adjudicated in the federal or state courts in the State of Delaware.

[signature page follows]

IN WITNESS WHEREOF, Assignor and Assignee hereto have each duly executed and delivered this Assignment as of the Effective Date hereinabove.

ASSIGNOR – Symbiomix Therapeutics, LLC



Name: Sean Moriarty

Title: Secretary

ASSIGNEE – Lupin Inc.



Name: Sean Moriarty

Title: Secretary

SCHEDULE A

PATENTS

DM Internal Docket No.	Patent No. & Issue Date	Title	Country/Region
Y7781-00003-US	U.S. Patent No. 10,335,390, issued July 2, 2019	Secnidazole For Use In The Treatment Of Bacterial Vaginosis	U.S.
Y7781-00005-JP	Japanese Patent No. 6487534, issued March 1, 2019	Secnidazole For Use In The Treatment Of Bacterial Vaginosis	Japan
Y7781-00007-AU	Australian Patent No. 2015-311674, issued June 21, 2018	Secnidazole For Use In The Treatment Of Bacterial Vaginosis	Australia

APPLICATIONS FOR PATENT

DM Internal Docket No.	Application No. & Filing Date	Title	Country/Region
Y7781-00002-US	U.S. Provisional Application No. 62/046,731, filed September 5, 2014	Secnidazole For Use In The Treatment Of Bacterial Vaginosis	U.S.
Y7781-00004-PCT	PCT International Application No. PCT/US15/48681, filed September 4, 2015	Secnidazole For Use In The Treatment Of Bacterial Vaginosis	PCT
Y7781-00006-CA	Canadian Patent Application No. 2,959,414, filed September 4, 2015	Secnidazole For Use In The Treatment Of Bacterial Vaginosis	Canada
Y7781-00008-KR	South Korean Patent Application No. 2017-7009154, filed September 4, 2015	Secnidazole For Use In The Treatment Of Bacterial Vaginosis	South Korea
Y7781-00009-PRO	U.S. Provisional Application No. 62/101,636, filed January 9, 2015	Secnidazole For Use In The Treatment Of Bacterial Vaginosis	U.S.
Y7781-00010-PRO	U.S. Provisional Application No. 62/126,178, filed February 27, 2015	Secnidazole For Use In The Treatment Of Melioidosis	U.S.
Y7781-00011-PRO	U.S. Provisional Application No. 62/126,251, filed February	Secnidazole For Use In The Treatment Of Melioidosis	U.S.

DM Internal Docket No.	Application No. & Filing Date	Title	Country/Region
	27, 2015		
Y7781-00012-PRO	U.S. Provisional Application No. 62/169,369, filed June 1, 2015	Novel Nitroimidazole Formulations And Uses Thereof	U.S.
Y7781-00013-US	U.S. Non-Provisional Application No. 15/170,572, filed June 1, 2016	Novel Nitroimidazole Formulations And Uses Thereof	U.S.
Y7781-00014-PCT	PCT International Application No. PCT/US16/35299, filed June 1, 2016	Novel Nitroimidazole Formulations And Uses Thereof	PCT
Y7781-00015-CA	Canadian Patent Application No. 2,988,082, filed June 1, 2016	Novel Nitroimidazole Formulations And Uses Thereof	Canada
Y7781-00016-PRO	U.S. Provisional Application No. 62/529,991, filed July 7, 2017	Novel Secnidazole Soft Gelatin Capsule Formulations And Uses Thereof	U.S.
Y7781-00019-US	U.S. Non-Provisional Application No. 13/839,804, filed March 15, 2013	Methods Of Treating Disease By Administering (R)-Secnidazole	U.S.
Y7781-00020-PCT	PCT International Application No. PCT/GB13/052344, filed September 6, 2013	Method Of Treating Disease By Administering (R)-Secnidazole	PCT
Y7781-00021-U.S.	U.S. Non-Provisional Application No. 13/839,834, filed March 15, 2013	Methods Of Treating Disease By Administering (R)-Secnidazole	U.S.
Y7781-00022-PCT	PCT International Application No. PCT/GB13/052345, filed September 6, 2013	Method Of Treating Disease By Administering (R)-Secnidazole	PCT
Y7781-00023-PCT	PCT International Application No. PCT/GB13/052343, filed September 6, 2013	Method Of Treating Disease By Administering (R)-Secnidazole	PCT
Y7781-00024-US	U.S. Non-Provisional Application No. 13/839,865, filed September 6, 2013	Method Of Treating Disease By Administering (R)-Secnidazole	U.S.

DM Internal Docket No.	Application No. & Filing Date	Title	Country/Region
Y7781-00029-US	U.S. Non-Provisional Application No. 16/049,032, filed July 30, 2018	Secnidazole For Use In The Treatment Of Bacterial Vaginosis	U.S.
Y7781-00030-AU	Australian Patent Application No. 2018203882, filed June 1, 2018	Secnidazole For Use In The Treatment Of Bacterial Vaginosis	Australia
Y7781-00031-US	U.S. Non-Provisional Application No. 16/014,809, filed June 21, 2018	Novel Secnidazole Soft Gelatin Formulations And Uses Thereof	U.S.
Y7781-00032-PCT	PCT International Application No. PCT/US2018/040743, filed July 3, 2018	Novel Secnidazole Soft Gelatin Formulations And Uses Thereof	PCT
Y7781-00033-AU-ADD	Australian Patent of Addition Application No. 2018217262, filed August 15, 2018	Secnidazole For Use In The Treatment Bacterial Vaginosis	Australia
Y7781-00037-JP-DIV1	Japanese Patent Application No. 2019-000253, filed January 4, 2019	Secnidazole For Use In The Treatment Bacterial Vaginosis	Japan
Y7781-00038-JP	Japanese Patent Application No. 2018-228992, filed December 6, 2018	Secnidazole For Use In The Treatment Bacterial Vaginosis	Japan
Y7781-00039-KR-DIV1	South Korean Patent Application No. 2019-7006430, filed March 4, 2019	Secnidazole For Use In The Treatment Bacterial Vaginosis	South Korea
Y7781-00041-US-DIV1	U.S. Non-Provisional Application No. 16/403,176, filed May 3, 2019	Secnidazole For Use In The Treatment Bacterial Vaginosis	U.S.
Y7781-00043-CA	Canadian Patent Application No. 3,046,521, filed June 13, 2019	Secnidazole For Use In The Treatment Bacterial Vaginosis	Canada
Y7781-00044-KR	South Korean Patent Application No. 2019-0088946, filed July 23, 2019	Secnidazole For Use In The Treatment Bacterial Vaginosis	South Korea
Y7781-00045-US-DIV2	U.S. Non-Provisional Application No.	Secnidazole For Use In The Treatment Bacterial	U.S.

DM Internal Docket No.	Application No. & Filing Date	Title	Country/Region
	16/586,339, filed September 27, 2019	Vaginosis	
Y7781-00046-US-DIV3	U.S. Non-Provisional Application No. 16/586,372, filed September 27, 2019	Secnidazole For Use In The Treatment Bacterial Vaginosis	U.S.